Published in Medical Letter on the CDC and FDA, March 28th, 2010
Peggy Farley, Chief Operating and Financial Officer asserts, "Bioheart's lead position in cell therapies for cardiovascular disease, along with its potential for generating revenues, is the reason for my confidence in the company's future earnings and therefore, the ultimate return on my investment. Adding to my existing investment in Bioheart allows me to take advantage of what I appraise as an unwarranted downturn in the company's stock price."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA